tetano
Editor, Senior Moderator
EClinicalMedicine
. 2021 Aug 30;101102.
doi: 10.1016/j.eclinm.2021.101102. Online ahead of print.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Raymund R Razonable[SUP] 1 [/SUP], Colin Pawlowski[SUP] 2 [/SUP], John C O'Horo[SUP] 1 [/SUP], Lori L Arndt[SUP] 3 [/SUP], Richard Arndt[SUP] 3 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Molly Destro Borgen[SUP] 1 [/SUP], Sara N Hanson[SUP] 4 [/SUP], Michelle C Hedin[SUP] 1 [/SUP], Patrick Lenehan[SUP] 2 [/SUP], Arjun Puranik[SUP] 2 [/SUP], Maria T Seville[SUP] 5 [/SUP], Leigh L Speicher[SUP] 6 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP], A J Venkatakrishnan[SUP] 2 [/SUP], Caroline G Wilker[SUP] 7 [/SUP], Andrew D Badley[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Real-world clinical data to support the use of casirivimab-imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab-imdevimab treatment of mild to moderate COVID-19.
Methods: A retrospective cohort of 696 patients who received casirivimab-imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion.
Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 52-71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab-imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5-3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2-4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4-5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups.
Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimab-imdevimab treatment was associated with a significantly lower rate of hospitalization.
Funding: Mayo Clinic.
Keywords: Casirivimab; Covid-19; Imdevimab; Monoclonal antibodies; Outcomes.
. 2021 Aug 30;101102.
doi: 10.1016/j.eclinm.2021.101102. Online ahead of print.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Raymund R Razonable[SUP] 1 [/SUP], Colin Pawlowski[SUP] 2 [/SUP], John C O'Horo[SUP] 1 [/SUP], Lori L Arndt[SUP] 3 [/SUP], Richard Arndt[SUP] 3 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Molly Destro Borgen[SUP] 1 [/SUP], Sara N Hanson[SUP] 4 [/SUP], Michelle C Hedin[SUP] 1 [/SUP], Patrick Lenehan[SUP] 2 [/SUP], Arjun Puranik[SUP] 2 [/SUP], Maria T Seville[SUP] 5 [/SUP], Leigh L Speicher[SUP] 6 [/SUP], Sidna M Tulledge-Scheitel[SUP] 1 [/SUP], A J Venkatakrishnan[SUP] 2 [/SUP], Caroline G Wilker[SUP] 7 [/SUP], Andrew D Badley[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 1 [/SUP]
Affiliations
- PMID: 34485873
- PMCID: PMC8404031
- DOI: 10.1016/j.eclinm.2021.101102
Abstract
Background: Real-world clinical data to support the use of casirivimab-imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab-imdevimab treatment of mild to moderate COVID-19.
Methods: A retrospective cohort of 696 patients who received casirivimab-imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion.
Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 52-71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab-imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5-3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2-4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4-5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups.
Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimab-imdevimab treatment was associated with a significantly lower rate of hospitalization.
Funding: Mayo Clinic.
Keywords: Casirivimab; Covid-19; Imdevimab; Monoclonal antibodies; Outcomes.